BNF:

Immune System & Malignant Disease

Status:

Do Not Prescribe (DNP), Red

Decision Date:

None

Comments

DO NOT PRESCRIBE (DNP): 

 

• NICE TA242: Colorectal cancer (metastatic) 2nd line. Bevacizumab - not recommended with fluoropyrimidines.  (Decision date - February 2012).
• NICE TA263: in combination with capecitabine for the first line treatment of metastatic breast cancer.  (Negative appraisal).  (Decision date - September 2012).
• NICE TA284: in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer.  (Decision date - July 2013).
• NICE TA285: in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer.  (Decision date - July 2013).
• NICE TA353: for treating relapsed platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer.  (Terminated appraisal).  (Decision date - September 2015).
• NICE TA436: for treating EGFR mutation-positive non-small-cell lung cancer.  (Terminated appraisal).  (Decision date - April 2017).
• NICE TA560: treating the first occurrence of platinum-sensitive advanced ovarian cancer.  (Terminated appraisal).  (Decision date - March 2019)

RED:

• NICE TA666:  with atezolizumab (decision date Jan 2021)
• NICE TA1136: Bevacizumab (originator and biosimilars) with fluoropyrimidine-based chemotherapy for metastatic colorectal cancer (Decision date March 2026)

This drug may be funded through the cancer drug fund - seek advice from the oncologist/haematologist/ NHS England.

 

Do Not Prescribe (DNP) Drug Classifications

• 6: Have NICE guidance that recommends they should not be used

Red Drug Classifications

• 8. NHS England commissioned – to be used in line with NHSE commissioning intentions

search again